• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Lybalvi: The Diet Olanzapine

Lybalvi: The Diet Olanzapine

January 31, 2022
Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Lybalvi is a new combo pill that aims to overcome the dreaded metabolic effects of olanzapine by pairing it with the opioid antagonist samidorphan. Patients still gain weight on Lybalvi, though not as much as they do on olanzapine. In the three controlled trials that compared the two drugs, the weight gain on Lybalvi was 5 lb less at six months, 3 lb less at three months, and no different at one month (Srisurapanont M et al, Sci Rep 2021;11(1):7583).


Where the drug falls short is in comparison to metformin, which reduced weight gain on various antipsychotics by 7 lb compared with placebo in a meta-analysis of 10 trials, most of which lasted three months, at a dose range of 750–2000 mg/day (Mizuno Y et al, Schizophr Bull 2014;40(6):1385–1403). Moreover, metformin improved insulin sensitivity, hemoglobin A1C, dyslipidemia, and prolactinemia on antipsychotics, while Lybalvi improved none of these.


Lybalvi could also be compared with naltrexone, an opioid antagonist with a similar pharmacodynamic profile to samidorphan. Naltrexone has weaker evidence when it comes to reducing weight gain on antipsychotics, showing effectiveness in only one of two trials. However, the naltrexone trials enrolled patients with actual obesity (BMI > 30 kg/m2), while patients in the Lybalvi trials were barely overweight (BMI 18–30, mean 25). This may have made a difference, as Lybalvi tended to work better in patients with lower BMI.


Lybalvi is approved in schizophrenia and bipolar I disorder, although the studies were limited to schizophrenia. The drug does not seem to exacerbate psychosis or add to the side effect burden of olanzapine. The manufacturer also sought approval for schizophrenia with alcohol use disorder, but a negative phase II trial halted that pursuit. To prevent opioid withdrawal, Lybalvi should not be started within seven days of taking a short-acting opioid or 14 days of a long-acting one. Most insurers require documentation of significant weight gain on olanzapine or failure of two generic atypical antipsychotics to cover Lybalvi, which retails for $1300 per month.


TCPR’S TAKE
Metformin is preferred over Lybalvi for weight gain on antipsychotics, as it brings about more meaningful metabolic benefits beyond the reduction in BMI.

General Psychiatry
KEYWORDS antipsychotics metabolic-syndrome metformin news_of_note novel-drug obesity olanzapine side-effects waist-circumference weight-gain weight-loss-medications
Aiken
Chris Aiken, MD.

Ask the Editor: Three Significant Food Interactions with ADHD Medications

More from this author
www.thecarlatreport.com
Issue Date: February 1, 2022
SUBSCRIBE NOW
Table Of Contents
An Off-Label Guide to Gabapentin
MDMA-Assisted Therapy for Severe PTSD
Lumateperone in Bipolar Depression
A Novel Treatment for Methamphetamine Use Disorder
Lybalvi: The Diet Olanzapine
Raising the Bar in Schizophrenia Treatment
CME Post-Test - Schizophrenia, TCPR, February 2022
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.